PTCHF Stock PureTech Health (PTCHF, $1.9) was a top quarterly gainer, rising +15.01%
at Tickeron.com
Loading...
PureTech Health (PTCHF, $1.9) was one of top quarterly gainers, jumping +1 to $1.9 per share. A.I.dvisor analyzed 781 stocks in the Biotechnology Industry over the last three months, and discovered that of them (6) charted an Uptrend while of them (3) trended down.
PTCHF sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for PTCHF moved above the 200-day moving average on December 03, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for PTCHF just turned positive on November 20, 2025. Looking at past instances where PTCHF's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
PTCHF moved below its 50-day moving average on November 24, 2025 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for PTCHF crossed bearishly below the 50-day moving average on November 24, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
The Aroon Indicator for PTCHF entered a downward trend on November 17, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.080) is normal, around the industry mean (27.324). P/E Ratio (9.882) is within average values for comparable stocks, (52.413). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.886). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (65.789) is also within normal values, averaging (326.858).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. PTCHF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PTCHF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Advertisement
General Information
Industry Biotechnology